AbCellera Biologics (ABCL) Construction in Progress (2023 - 2025)

AbCellera Biologics (ABCL) has 3 years of Construction in Progress data on file, last reported at $2.2 million in Q4 2025.

• Quarterly Construction in Progress fell 97.87% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 97.87% YoY) and the FY2025 annual result came in at $2.2 million, down 97.87% from the prior year.
• Construction in Progress eased to $2.2 million in Q4 2025, from $118.7 million in the prior quarter.
• In the past five years, Construction in Progress ranged from a high of $118.7 million in Q3 2025 to a low of $2.2 million in Q4 2025.
• A 3-year average of $31.4 million and a median of $15.2 million in 2024 frame the typical range for Construction in Progress.
• The widest YoY moves for Construction in Progress: up 670.78% in 2025, down 97.87% in 2025.
• Tracing ABCL's Construction in Progress over 3 years: stood at $13.7 million in 2023, then surged by 653.28% to $103.2 million in 2024, then slumped by 97.87% to $2.2 million in 2025.
• The last three Construction in Progress figures came in at $2.2 million (Q4 2025), $118.7 million (Q3 2025), and $23.1 million (Q2 2025), per Business Quant data.